Mucormycosis in COVID-19

Completed

• Conditions: Covid19; Candida Infection; Mucormycosis; Aspergillosis

• Registration Number: NCT04935463
• Lead Sponsor: Montefiore Medical Center

Brief Summary

The purpose is to allow phsyician reporters to contribute to MUNCO registry. Mucormycosis in COVID-19 is a rapidly escalating medical emergency reported in high numbers in India during the ongoing coronavirus surge. There is very little known about the risk factors, patterns and complications of mucormycosis as it occurs either during the infection or treatment phase of the novel coronavirus (COVID-19). In light of this emerging epidemic within a pandemic, it is of time sensitive importance to obtain a better understanding of the risk factors and outcomes of this fatal complication

Detailed Description

Not available

Study Timeline

• Study Start: 2021-05-24
• Study First Submitted: 2021-06-21
• Study First Submitted QC: 2021-06-21
• Study First Posted: 2021-06-23
• Primary Completion: 2022-03-01
• Study Completion: 2022-03-01
• Status Verified: 2023-04
• Last Update Submitted: 2023-04-14
• Last Update Posted: 2023-04-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 728

Inclusion Criteria

Diagnosed case of Mycotic Infection in COVID-19

Exclusion Criteria

• None

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Vision loss	60 days

Trial Locations

Locations (1)

Montefiore Medical Center; 🇺🇸 Bronx, New York, United States